Navigation Links
ASAM Approves Prescription Drug Policy
Date:1/26/2012

CHEVY CHASE, Md., Jan. 26, 2012 /PRNewswire-USNewswire/ -- "Prescription drug diversion and the health consequences of prescription drug misuse and abuse should be of primary concern to all physicians," states American Society of Addiction Medicine (ASAM) Acting President, Stuart Gitlow, MD.  "Tens of thousands of Americans are overdosing on prescription pain medication and many of these prescriptions are coming from doctors' offices." 

Chronic pain and addiction are issues faced by patients from all walks of life and in all types of treatment settings.  And, yet, very few physicians are sufficiently educated about the potential psychiatric and addiction consequences of prescribing scheduled medications like opioid analgesics and sedative hypnotics (two of the most commonly misused classes of prescription medication).  The Centers for Disease Control and Prevention reports that the sale of prescription pain drugs has increased by 300% since 1999 and the most recent National Survey on Drug Use and Health (Substance Abuse and Mental Health Administration) reports that nearly 1 in 6 non-medical users of prescription pain killers got the drug through a prescription from a doctor.  Currently, there are no requirements that prescribers prove they are competent to prescribe these potentially lethal drugs. 

"Prescription drug use and overdose death are becoming a public health crisis," says Dr. Gitlow.  "Physicians and patients should understand the risks and benefits of using these powerful drugs and make educated treatment choices."  To that end, ASAM recommends that all health professionals who can prescribe scheduled medications must be included in any educational efforts to improve patient outcomes and public health.  One part of the solution is to mandate prescriber education for all health professionals licensed to prescribe, dispense or administer prescription drugs.  A public health response should also include patient education, training for medical students and residents in safe prescribing practices, pain medicine and addiction medicine, implementation of coordinated state prescription drug monitoring programs, and support for continued research on patterns of manufacture, distribution and sales of psychoactive drugs which have the potential for diversion and misuse. 

To read ASAM's Public Policy Statement on Measures to Counteract Prescription Drug Diversion, Misuse and Dependence, please click here.

The American Society for Addiction Medicine is a professional society representing close to 3,000 physicians dedicated to increasing access and improving quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addictions.

Contact: Alexis Geier-Horan
(301) 656-3920 x103
ageier@asam.org
www.asam.org


'/>"/>
SOURCE American Society of Addiction Medicine
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest ... its plans to open a flagship location in Covington, LA at 401 N. U.S. ... Go store next to Office Depot in the Holiday Square shopping center. Its location ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):